healthcare

Achillion Pharmaceuticals Gears Up for Secondary Offering

Shares of Achillion Pharmaceuticals Inc. (NASDAQ: ACHN) saw a handy gain on Thursday after the company announced a secondary offering. While the offering is set to close on November 20, ...
Read Full Story »

Acorda Therapeutics Gets Crushed After Halting Parkinson’s Trial

Acorda Therapeutics Inc. (NASDAQ: ACOR) saw its shares drop sharply following an update on its Parkinson’s trial. The company paused new enrollment in the long-term safety studies, pending further discussion ...
Read Full Story »

Loxo Loses Out Despite Signing Big Cancer Deal

Loxo Oncology Inc. (NASDAQ: LOXO) saw its shares dip on Tuesday after the company announced that it will be partnering with Bayer to develop and commercialize larotrectinib and LOXO-195. Even ...
Read Full Story »

Why Argus Is Taking a Step Back on Gilead Sciences

Gilead Sciences Inc. (NASDAQ: GILD) saw its shares take a step back on Monday after an independent research firm downgraded the stock. Many investors have hoped that the shares will ...
Read Full Story »

Short Sellers Back Way Off Major Pharma

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

3 Companies Spearheading the Antibiotics Space in 2018

This may turn out to be a pivotal year in antibiotic development, after decades of dramatic decline in the space. While 1980 to 1984 saw 18 new antibiotic approvals, the ...
Read Full Story »

Short Sellers Grow More Selective on Major Biotechs

The short interest data are out for the most recent settlement date, October 31. Generally speaking, companies within the biotech industry are considered to be a riskier group of stocks, ...
Read Full Story »

Sage Therapeutics Wins Big in Depression Trial

Sage Therapeutics Inc. (NASDAQ: SAGE) shares absolutely exploded on Thursday after the firm announced top-line results from its late-stage trial in severe postpartum depression (PPD). Ultimately the Phase 3 clinical ...
Read Full Story »

Why Otonomy Shares Are Skyrocketing

Otonomy Inc. (NASDAQ: OTIC) reported its most recent quarterly results after the markets closed on Wednesday and gave an update on its late-stage trial in patients with Ménière’s disease. Although ...
Read Full Story »

Voyager Therapeutics Gears Up for Secondary Offering

Voyager Therapeutics Inc. (NASDAQ: VYGR) has seen a decent year for its shares and now seems like a good time to cash in. Although the past month has not been ...
Read Full Story »

Keryx Biopharmaceuticals FDA Win Outweighed by Q3 Loss

Keryx Biopharmaceuticals Inc. (NASDAQ: KERX) shares took a big step back on Tuesday after the company announced its third-quarter results and an update from the U.S. Food and Drug Administration ...
Read Full Story »

Why Solid CVS Health Earnings Are Not Enough

When CVS Health Corp. (NYSE: CVS) reported its third-quarter financial results early Monday, the company said that it had $1.50 in earnings per share (EPS) on $46.2 billion in revenue. ...
Read Full Story »

Sarepta Takes Another Big Step Forward With DMD Treatment

Sarepta Therapeutics Inc. (NASDAQ: SRPT) saw its shares hit a new multiyear high on Friday after the firm announced that it received a key approval from the U.S. Food and ...
Read Full Story »

2 Reports on Climate Change Cite Progress, Challenges

The impacts of climate change are "undermining the social and environmental determinants that underpin good health," according to a new report from British medical journal The Lancet. If the global ...
Read Full Story »

Intellia Therapeutics Gears Up for Secondary Offering

Intellia Therapeutics Inc. (NASDAQ: NTLA) saw its shares take a dip on Thursday after the firm announced the pricing of its secondary offering. Looking at the chart, this seems to ...
Read Full Story »